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Background. To describe the methodology of a study designed to determine whether systemic sclerosis (SSc) patients with incident
sclerodermarenalcrisis(SRC)onangiotensinconverting enzyme (ACE)inhibitorspriortotheonsetofSRChaveworseoutcomes.
Methods. Prospective, international cohort study of SRC subjects identiﬁed through an ongoing web-based survey. Every second
Friday afternoon, an e-mail was sent to 589 participating physicians to identify new cases of SRC. Death or dialysis at one year
after the onset of SRC will be compared in patients exposed or not to ACE inhibitors prior to the onset of SRC. Results.F i f t e e n
months after the start of the survey, we had identiﬁed 76 incident cases of SRC. Of these, 66 (87%) had a hypertensive SRC and 10
(13%) a normotensive SRC. Twenty-two percent (22%) of the patients were on an ACE inhibitor immediately prior to the onset
of the SRC. To date, we have collected one-year follow-up data on approximately 1/3 of the cohort. Of these, over 50% have died
or remain on dialysis at one year. Conclusion. An international, web-based cohort study design is a feasible method of recruiting a
substantial number of patients to study an infrequent vascular manifestation of SSc.
1.Introduction
Scleroderma renal crisis is an infrequent but life-threatening
complicationofsystemicsclerosis(SSc)[1].Itwaspreviously
associated with signiﬁcant morbidity, including chronic
renal failure and dialysis, and high mortality. However,
since the advent of angiotensin converting enzyme (ACE)
inhibitors, the outcome of SRC has improved dramatically
[2]. There is also a perception among experts that the
incidence of SRC has fallen over the past years. This is
thought to be due in part to the more liberal use of ACE
inhibitors to treat Raynaud’s phenomenon and hypertension
in SSc [3].
Given the beneﬁts of ACE inhibitors in SRC and the
perceived decrease in incidence in SRC, some experts have
advocated the use of prophylactic ACE inhibitors even in the
absence of Raynaud’s or hypertension [3]. However, others
have argued that there is no clear rationale for this since it
has been demonstrated that most SSc patients do not have
hyper-reninemia prior to the onset of SRC [4]. In addition,
recent retrospective data in patients with SRC suggested that
ACE inhibitors prior to the onset of SRC may have worse
outcomes than those not taking these drugs [5–7]. This has
been hypothesized to be due to the fact that those on ACE
inhibitors may have normotensive SRC and diagnosis may
thus be delayed in these patients.
Given the belief that the incidence of SRC seems to
have fallen over the past years due to the increasing use of
ACE inhibitors, some experts have proposed undertaking
a large, simple randomized trial to conﬁrm this ﬁnding
[8]. However, concerns based on the preliminary data that
suggests that patients taking ACE inhibitors who develop2 International Journal of Rheumatology
Hypertensive SRC:
Systolic blood pressure >140mmHg
Diastolic blood pressure >90mmHg
Rise in systolic blood pressure >30mmHg compared to baseline
Rise in diastolic blood pressure >20mmHg compared to baseline
AND
One of the following features:
(a) Increase in serum creatinine >50% over baseline OR serum creatinine >120% of upper limit of normal for local laboratory,
(b) Proteinuria: >2+ by dipstick and conﬁrmed by protein:creatinine ratio >upper limits of normal (ULN),
(c) Hematuria: >2+ by dipstick or >10 RBCs/HPF (without menstruation),
(d) Thrombocytopenia: ≤100,000plts/mm3,
(e) Hemolysis: by blood smear or increased reticulocyte count,
(f) Hypertensive encephalopathy.
Normotensive SRC:
Increase in serum creatinine >50% over baseline OR serum creatinine >120% of upper limit of normal for local laboratory
AND
One of the following features:
(a) Proteinuria: >2+ by dipstick and conﬁrmed by protein:creatinine ratio > upper limits of normal (ULN),
(b) Hematuria: >2+ by dipstick or >10 RBCs/HPF (without menstruation),
(c) Thrombocytopenia: ≤100,000 plts/mm3,
(d) Hemolysis: by blood smear or increased reticulocyte count,
(e) Hypertensive encephalopathy.
Box 1: Proposed characteristics of SRC.
SRC may have worse outcomes remain. Thus, prior to
undertaking a large, randomized trial, we believed that there
was a real need to obtain additional data to assess whether in
fact the use of ACE inhibitors prior to the onset of SRC was
associated with worse outcomes.
We therefore undertook a study to determine whether
SSc patients with incident SRC on ACE inhibitors immedi-
ately prior to the onset of SRC have worse outcomes, deﬁned
as dialysis dependence or death after one year than those not
on these drugs prior to the onset of SRC. The purpose of this
paperistodescribethemethodologyandpreliminarydataof
this study. In particular, we wish to highlight the advantages
anddisadvantagesassociatedwithusingsurveymethodology
via the internet to study uncommon vascular manifestations
of SSc.
2. Methods
2.1. Design. Prospective, international cohort study of sub-
jects identiﬁed through an ongoing web-based survey.
2.2. Study Subjects. In September 2008, we compiled an e-
mail list of physicians with an interest in SSc from the
Canadian Scleroderma Research Group, the Scleroderma
Clinical Trials Consortium, the EULAR Scleroderma Trials
and Research (EUSTAR) group, and other international
collaborators, in particular from Colombia, Mexico, and
Australia. They were contacted and invited to participate in
the web-based survey. Thereafter, 589 participating physi-
cians were sent an e-mail every second Friday afternoon
asking them simply: “Have you diagnosed a case of SRC in
thepasttwoweeks”.Theywereaskedtocheckayes/nobox.If
the answer was no, and in most cases it was, then that was all
that was required of them for that period. If the answer was
yes, they were then asked to answer a simple, short survey
about their case requiring about 5 minutes to complete. The
survey was developed and conducted using SurveyMonkey,
a simple, inexpensive, web-based survey tool. We initially
intended to collect cases over a 52-week period, but since we
were still identifying new cases at the end of that period, we
chose to continue the survey beyond that point.
2.3. Deﬁnition of SRC. For the purposes of the study, a
patient was diagnosed with SRC if he/she was diagnosed with
SRC by the recruiting physician. We nevertheless collected
data on the signs and symptoms that the physicians relied
on to make their diagnosis (Box 1).
2.4. Covariates. The survey allowed us to collect data on the
following variables:
(1) patient demographics (age, sex, race/ethnicity),
(2) disease characteristics (limited versus diﬀuse, disease
duration, autoantibodies),
(3) blood pressure and renal function prior to the onset
of the SRC,
(4) current use of ACE inhibitor or ARB immediately
prior to SRC onset, and if so, reasons for such
use (Raynaud’s, hypertension, prophylaxis because of
concurrent corticosteroid use, simple prophylaxis);
name of drug, current dose,
(5) concomitant medications, including glucocorticoids,
cyclosporine and nonsteroidal anti-inﬂammatories,
(6) signs and symptoms used to diagnose SRC.International Journal of Rheumatology 3
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Figure 1: Rate of recruitment of study subjects.
2.5. Outcomes. The primary outcomes of interest were
deﬁned as death or dialysis one year after the onset of SRC.
Secondary outcomes included renal function after one year.
One year after a patient was identiﬁed, a simple follow-up
case report form is sent to the recruiting physician. At study
completion, the rates of dialysis or death after one year in
SSc patients with SRC exposed to ACE inhibitors at the time
when they developed SRC will be compared to the rates in
those not on ACE inhibitors at the time they developed their
SRC.
2.6. Sample Size Considerations. The main objective of this
study was to determine whether there was harm associated
with using ACE inhibitors prior to the onset of SRC. In
computing an estimated sample size, we made the following
assumptions: (1) estimated prevalence of ACE inhibitor
exposure prior to the onset of SRC approximately 25% (ratio
of exposed to non-exposed 1:3); (2) prevalence of death or
dialysis after one year in the nonexposed of approximately
50%[2];(3)riskofdeathordialysisassociatedwithexposure
approximatelytwofold[5],and(4)losstofollow-upofabout
10%. We thus calculated that a total sample of approximately
60 subjects would be needed to have 80% power to detect the
estimated increased risk in poor outcomes in those exposed
compared to those unexposed to ACE inhibitors.
2.7. Ethical Considerations. Central research ethics approval
was obtained for this study from the ethics review board
of the Jewish General Hospital, Montreal, Canada. Some
recruiting physicians also sought local ethics approval prior
to enrolling patients into the survey.
3. Results
As of February 2010, ﬁfteen months after the start of the
survey, we had identiﬁed 76 incident cases of SRC (Figure 1).
Mean age of the cohort was 53 (±12 years), 68% were
women, 72% were White, 68% had diﬀuse SSc, and median
disease duration since the onset of the ﬁrst non-Raynaud’s
symptom was 1.5 years (Table 1). Approximately half of the
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Figure 2: Autoantibodies.
cases were from Canada and the United States, and the other
half from elsewhere around the world. Fifteen percent (15%)
of patients were positive for an RNA polymerase autoanti-
body (although not all centers tested for this antibody) and
42% for a speckled antinuclear antibody (Figure 2).
Of the 76 patients, 66 (87%) had a hypertensive SRC and
10 (13%) a normotensive SRC according to the recruiting
physician. Twenty-two percent (22%) of the patients were
on an ACE inhibitor and 5% on an ARB immediately prior
to the onset of the SRC (Table 2). Of these, 16 of the 66
(24%) with hypertensive crisis and 5 of the 10 (50%) with
normotensive crisis were on an ACE inhibitor or an ARB
prior to the onset of SRC. Over 50% of the patients were also
on glucocorticoids immediately prior to the onset of SRC, at
a mean dose of 17mg/d of prednisone (or its equivalents).
Of the 66 patients classiﬁed as hypertensive, 64 satisﬁed
the proposed criteria for hypertensive SRC mentioned in
Box 1. Of the 10 patients classiﬁed as normotensive, 4 satis-
ﬁed the proposed criteria for normotensive SRC mentioned
in Box 1.
To date, we have collected one-year follow-up data on
approximately 1/3 of the cohort. Of these, over 50% have
died or remained on dialysis after one year. Collection of
one-year follow-up data on the remainder of the patients is
ongoing.
4. Discussion
Whether ACE inhibitors are associated with a worse progno-
sis for patients with SRC is an important clinical question,
in particular given the widespread availability of these drugs
andtheirperceivedbeneﬁtsinreducingtheincidenceofSRC.
However, given the rarity of SRC, designing a prospective
study to address this question is not without consider-
able logistical problems. Using an international, web-based
cohort study design, we identiﬁed 76 incident SRC cases over4 International Journal of Rheumatology
Table 1: Baseline characteristics of cohort (N = 76).
Mean (SD) age, years (SD) 53.3 (12.4)
Women, N (%) 52 (68.4)
Ethnic groups, N (%)
White 55 (72.4)
Black 12 (15.8)
Asian 4 (5.3)
Hispanic 3 (4.0)
Native American 2 (2.6)
Disease subsets, N (%)
Diﬀuse disease 52 (68.4)
Limited disease 19 (25.0)
Sine scleroderma 5 (6.6)
Disease duration (since ﬁrst non-Raynaud’s
symptom)
Median disease duration, years (IQR) 1.47
(0.87, 4.21)
Number (%) with disease duration < 1 year 24 (32)
Countries of origin of study subjects, N
Australia 2
Belgium 1
Brazil 1
Canada 13
Denmark 2
Dominican Republic 1
France 2
Germany 2
Ghana 1
Greece 1
Haiti 2
Hungary 3
Israel 1
Italy 2
Korea 1
Norway 3
Pakistan 3
Poland 1
Spain 2
Switzerland 2
The Netherlands 1
Turkey 3
USA 26
approximately 15 months. We thus believe that this is a feasi-
ble method of recruiting a substantial number of patients to
study this infrequent vascular manifestation of SSc.
We had made several assumptions to compute our
desired sample size, including that approximately 25% of
subjectswouldbeexposedtoACEinhibitorsandthattherate
of death and/or dialysis after one year would approach 50%.
The numbers presented in this preliminary analysis support
these assumptions. Thus, after approximately one more year
Table 2: Characteristics of study patients (N = 76).
N (%)
Hypertensive SRC 66 (86.8)
Normotensive SRC 10 (13.2)
ACE inhibitor immediately prior to SRC onset 17 (22.4)
ARB immediately prior to SRC onset 4 (5.3)
Glucocorticoids immediately prior to SRC onset 39 (51.3)
Mean prednisone dose in prednisone equivalents 16.7
mg/day
Nonsteroidal anti-inﬂammatory drugs
immediately prior to SRC onset 9 (11.8)
Cyclosporine immediately prior to SRC onset 1 (1.3)
SRC: scleroderma renal crisis, ACE: angiotensin converting enzyme, and
ARB: angiotensin receptor blocker.
of follow-up, we should have suﬃcient power to address the
important clinical question of the prognosis of patients who
develop SRC while on ACE inhibitors compared to those not
on these medications.
In order to maximize enrollment for this study, we
compiled an extensive list of 589 physicians from around
the world with an apparent interest in SSc (i.e., identiﬁed
from well-established SSc research groups and through
international SSc networks), we designed a simple survey
requiring less than 5 minutes to complete and we sent out
the survey every 2 weeks so as to increase the possibility
that the recruiting physician would have easy access to the
clinical data. We were especially careful in including incident
cases. Indeed, many physicians contacted us to enquire
whether they could enroll patients who had had their SRC
in the past and were being seen in follow-up. Unfortunately,
those patients were not eligible because, having survived
their SRC suﬃciently long, these prevalent cases were in
fact “survivors” and including them could have biased our
results.
We encountered several problems in the course of the
study. The most important one was that there was no gold
standard to deﬁne SRC. Given that the recruiting physicians
were identiﬁed through SSc research groups and had an
apparent interest in SSc, we chose to rely on their “expert”
opinion. Moreover, we also collected data on the signs and
symptoms that they relied on to make their diagnosis. In this
preliminary analysis, most patients satisﬁed the proposed
criteria for hypertensive SRC (Box 1). However, additional
work will be needed to validate a more sensitive deﬁnition
of normotensive SRC.
Another issue that arose was that of ethics approval.
The study had been approved by the principal investigators’
ethics committee, the data collected for the purposes of
this study were obtained through chart review by a treating
physician, no direct patient contact was required, and
patients were identiﬁed using depersonalized study codes.
Nevertheless, some recruiting physicians preferred to obtain
ethics approval from their local ethics committees. Unfortu-
nately, this imposed a certain workload on them and we did
not have funds to support them in this regard. Although thisInternational Journal of Rheumatology 5
Table 3: Signs and symptoms of SRC.
Patients with hypertensive SRC (N = 66) N (%)
Systolic blood pressure >140 mmHg 64 (97)
Diastolic blood pressure > 90 mmHg 54 (82)
Rise in systolic blood pressure >30 mmHg compared to baseline 46 (70)
Rise in diastolic blood pressure >20 mmHg compared to baseline 37 (56)
Increase in serum creatinine >50 % above baseline OR serum creatinine > 120% of upper limit of normal for local laboratory 60 (91)
Proteinuria: >2+ by dipstick and conﬁrmed by protein:creatinine ratio > upper limits of normal 25 (38)
Hematuria: >2+ by dipstick or >10 RBCs/HPF (without menstruation) 18 (27)
Thrombocytopenia: < 100,000 platelets/mm3 20 (30)
Hemolysis: by blood smear or increased reticulocyte count 27 (41)
Hypertensive encephalopathy 9 (14)
Patients with normotensive SRC (N = 10) N (%)
Systolic blood pressure >140 mmHg 2 (20)
Diastolic blood pressure >90 mmHg 2 (20)
Rise in systolic blood pressure >30 mmHg compared to baseline 3 (30)
Rise in diastolic blood pressure >20 mmHg compared to baseline 2 (20)
Increase in serum creatinine >50% above baseline OR serum creatinine > 120% of upper limit of normal for local laboratory 9 (90)
Proteinuria: >2+ by dipstick and conﬁrmed by protein:creatinine ratio > upper limits of normal 5 (50)
Hematuria: >2+ by dipstick or >10 RBCs/HPF (without menstruation) 4 (40)
Thrombocytopenia: <100,000 platelets/mm3 2 (20)
Hemolysis: by blood smear or increased reticulocyte count 3 (30)
Hypertensive encephalopathy 1 (10)
may have delayed initial recruitment in those centers, many
participantsnonethelesspursuedethicsapprovalpresumably
based on enthusiasm for the project.
Thirdly, although the tool that we used to create the
survey was very user-friendly, inexpensive, and allowed us
to integrate important data quality checks, it allows only
basic data analysis. More detailed analysis will require time-
consuming data manipulation to transfer the data into more
sophisticated programs. Alternative data acquisition formats
are available and could be considered for future studies
involving more complicated analyses.
Finally, we have had to invest a lot of eﬀort in obtaining
one-year follow-up data. The follow-up case report form is
somewhatlongerandrequiresapproximatelytwentyminutes
to complete. A central research assistant has had to work
diligently to encourage recruiting physicians to complete
these forms. Contacting them personally by telephone has
resulted in improved follow-up data collection. We did not
have funds to pay for local research assistants to ﬁll the
follow-up forms. Whether this could also have contributed
to more eﬃcient collection of follow-up data thus remains
unknown.
Our study will be unable to answer another very
important question; that is, whether ACE inhibitors are
associated with a reduction in the incidence of SRC. That
studywouldrequirefollowingpatientswithmostlyearlySSc,
some exposed and others unexposed to ACE inhibitors, until
the occurrence of SRC. Since SRC is infrequent, the sample
size for such a cohort study exceeds 1000. Nevertheless, that
studyusingourcurrentdesigncouldbefeasible.Recruitment
would most likely have to occur over several years and
strategies to maintain interest in recruitment would have to
be developed. Careful collection of follow up data would also
be necessary. On the other hand, the costs of maintaining an
ongoing web-based survey are really quite minimal.
This study has some limitations. First, our response rate
remains largely uncertain. When we sent the biweekly e-
mails, we asked the participants to answer whether or not
they had seen a case of SRC in the past two weeks, and
if so, go on to ﬁll out the survey. Unfortunately, many
participants did not respond to the biweekly e-mails. Thus,
it is diﬃcult to know whether they indeed had not seen
a case or whether they were not participating (during that
particular time period). It is possible that some cases were
seenbutnotenteredintothesurvey,anditisconceivablethat
their disease characteristics may have been diﬀerent from
thoseofthecasesincludedinthesurvey(e.g.,somemayhave
had worse and others milder disease). Thus, the response
rate and the eﬀect of a nonresponse bias in this study are
uncertain. Second, patients who did not have access to a
participatingphysicianorthosewithsubclinicaldisease(e.g.,
normotensive SRC) whose SRC may have been overlooked
by a physician were not captured in this survey. Thus, our
results are generalizable to patients diagnosed with SRC and
entered into this survey by a participating physician. On
the other hand, every two weeks we contacted well over
550 participants identiﬁed as members of well-established
scleroderma research groups or colleagues of such groups6 International Journal of Rheumatology
from around the world. SRC is a serious complication of
SSc and we thus believe that many if not most SRC cases
were, at some point, brought to the attention of one of these
perceived SSc experts.
In conclusion, using an international, web-based
prospective cohort design, we identiﬁed 76 incident of SRC
cases over approximately 15 months. Twenty-two percent
(22%) of them were on an ACE inhibitor immediately
prior to the onset of their SRC. Follow-up data collection
to determine rates of death and/or dialysis after one year
according to exposure to ACE inhibitor prior to SRC onset is
ongoing. The methodology used for this study is innovative
and emphasizes that interinstitutional and international
collaboration can contribute signiﬁcantly to the study of
infrequent vascular manifestations of SSc. The ultimate
success of this study will depend largely on the goodwill of
the recruiting physicians who will have to invest additional
time and eﬀort in collecting and providing us with the
most complete follow-up data possible. Their dedication
will hopefully allow us to answer one of the most pressing
ongoing questions related to SRC in the near future.
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